CSL (OTCMKTS:CSLLY) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of CSL (OTCMKTS:CSLLY) to a strong-buy rating in a research note issued to investors on Thursday,Zacks.com reports.

CSL Stock Performance

Shares of CSLLY stock opened at $86.16 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18. CSL has a fifty-two week low of $83.31 and a fifty-two week high of $109.00. The business has a fifty day simple moving average of $89.07 and a 200-day simple moving average of $96.46.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.